# Contact Legal PT-141: Editorial Inquiries About the Bremelanotide Digest

> Contact Legal PT-141 with corrections or editorial inquiries about the PT-141 (bremelanotide) research digest. Editorial only — not a clinic, not a vendor, no medical or prescription services.

Editorial inquiries and corrections about the PT-141 (bremelanotide) digest.

## Editorial inquiries

Use the form below to reach Legal PT-141 about the PT-141 (bremelanotide) digest. We welcome corrections, citation suggestions, and notes from researchers who can point us to additional peer-reviewed sources or label updates we should incorporate.

This is an editorial publication only. We cannot answer medical questions, advise on whether any compound is appropriate for any person, or provide dosing, prescription, or clinical guidance. We do not sell, source, supply, or broker any product, and we cannot help with obtaining anything. Questions of that kind belong with a qualified healthcare professional, not with an editorial digest.

## What to expect

Messages are read as editorial correspondence. If you are flagging an inaccuracy, a citation that points to the wrong study, or a figure that needs updating against the current FDA label or a newer trial, that feedback is the most useful thing you can send — accuracy against the published record is the entire point of this site.

We do not provide individualized advice of any kind, and a reply is not medical, legal, or professional guidance. For anything concerning your own health, consult a licensed clinician.

---

A documentation-grade reading of the bremelanotide record — the approved label and the Phase 3 endpoints logged to source, the effect-size debate left in plain view, and the field reports fenced off from the evidence; not a clinic, not a vendor, not a prescription.